Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Madison's GenTel partners with Taiwan firm
Madison, Wis. - GenTel BioSurfaces, Inc., a privately held life sciences company, has partnered with Taiwan-based Abnova Corp., the world's largest monoclonal antibody manufacturer, to combine Abnova's protein and antibody content manufacturing capabilities with GenTel's new custom multiplex immunoassay developm......
Full article >>>
'"/>
Source:wistechnology.com By WTN News 11/14/05
Related biology technology :
1. Madisons PunchStock acquired by Getty Images
2. UW-Madisons Beebe wins scientific award
3. Madisons downtown wireless network almost ready
4. Group honors UW-Madisons Stunden for IT leadership
5. International eyes drawn to Madisons games research
6. GenTel acquires GlaxoSmithKline chip platform
7. New angel capital centered on GenTel agreement with big pharma
8. GenTel licenses next generation cancer research
9. GenTel to distribute cancer research tool
10. GenTel gets federal grant to develop allergy test
11. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
Post Your Comments:
(Date:3/4/2015)... PRC Clinical, a full-service, ... Bay Area, will exhibit and present at the ... on March 25th and 26th in Tel Aviv, Israel. ... Israeli life science companies seeking to conduct U.S. Food ... span all phases of human trials, from Phase I ...
(Date:3/4/2015)... March 4, 2015 BioClinica®, Inc., a ... provider, today announced that clinical trial professionals ... at its annual European User Conference in ... discuss the use of its eClinical technologies ... technologies include: the Microsoft Office-Smart OnPoint CTMS; ...
(Date:3/4/2015)... PARIS , March 4, 2015 ... de Paris in December 2011, ... study of yttrium-90 resin microspheres versus sorafenib in advanced ... results expected late 2016. SARAH, a ... liver cancer (hepatocellular carcinoma, or HCC) has completed patient ...
(Date:3/3/2015)... 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: ... diagnostics that target the underlying mechanisms of cancer, today ... ended December 31, 2014. Effective July 17, ... May 31 to December 31. As a result of ... for the quarter and the seven months ended December ...
Breaking Biology Technology:PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12[0] PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv[0] BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe[0] Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016[0] Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014
... May 27 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE ... been enrolled in its randomized, double-blind trial evaluating nimotuzumab in ... Institute - New Hope. This trial initiation follows recent clearance ... allowing the Company to enroll patients at US clinical ...
... WALTHAM, Mass. , May 27 Repligen Corporation ... Drug Administration (FDA) and the European Medicines Agency (EMA) have ... Phase 3 study to establish the utility of RG1068, synthetic ... pancreas (Phase 3 re-read). The FDA and EMA have agreed ...
... engineering in the College of Engineering at Virginia Tech, ... Award to support development of a carbon nanotube-enhanced composite ... of huge wind turbine blades. Powe awards provide ... (ORAU) member institutions. These awards are intended to enrich ...
Cached Biology Technology:YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab 2YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab 3YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab 4YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab 5YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab 6Repligen Announces FDA and EMA Approval of Re-analysis of Images from Phase 3 Trial of RG1068 for Pancreatic Imaging 2Repligen Announces FDA and EMA Approval of Re-analysis of Images from Phase 3 Trial of RG1068 for Pancreatic Imaging 3Repligen Announces FDA and EMA Approval of Re-analysis of Images from Phase 3 Trial of RG1068 for Pancreatic Imaging 4Repligen Announces FDA and EMA Approval of Re-analysis of Images from Phase 3 Trial of RG1068 for Pancreatic Imaging 5Powe Award supports development of nanocomposites to monitor wind turbine blade structure 2YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumabRepligen Announces FDA and EMA Approval of Re-analysis of Images from Phase 3 Trial of RG1068 for Pancreatic ImagingPowe Award supports development of nanocomposites to monitor wind turbine blade structure
(Date:2/12/2015)... Conn. , Feb. 12, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62/113114 for DISTRIBUTED ... DEVICES. The patent further establishes NXT-ID,s position ... its intellectual property portfolio the ability for multiple devices ...
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... Jan. 27, 2015 Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4... Insulin resistance, the hallmark of type 2 diabetes and ... an apparent contributor to muscle wasting and severe fat ... And in an animal study, a diabetes drug ... wasting and fat loss, the main consequences of a ...
... RICHLAND, Wash. -- An analytical chemist at the ... recognized with a National Institutes of Health Director,s New ... to make new research and clinical diagnostic tools that ... technologies. The award, which comes with a $1.5 ...
... University of North Carolina at Chapel Hill School of ... received prestigious awards from the National Institutes of Health ... Klaus Hahn, Ph.D., and Mark Zylka, Ph.D., have ... is also in the UNC College of Arts and ...
Cached Biology News:Diabetes drug shows promise in fighting lethal cancer complication 2Diabetes drug shows promise in fighting lethal cancer complication 3PNNL chemist earns NIH New Innovator Award 2PNNL chemist earns NIH New Innovator Award 3UNC scientists garner new NIH awards for high risk, transformative research 2UNC scientists garner new NIH awards for high risk, transformative research 3UNC scientists garner new NIH awards for high risk, transformative research 4ma. plate stack height 70mm...
... MBS Satellite Thermal Cycler (MBS) ... solution for medium to high ... combines the latest in satellite ... and PC control, resulting in ...
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
Glycerokinase; from Bacillus stearothermophilus...
Biology Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |